Clinical trials for trastuzumab biosimilars

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Clinical trials for trastuzumab biosimilars

Biosimilars/General | Posted 28/08/2020 0 Post your comment

Roche’s originator trastuzumab biological (Herceptin) was approved by the US Food and Drug Administration (FDA) in September 1998 and by the European Medicines Agency (EMA) in August 2000 [1]. The patents on Herceptin expired in Europe in July 2014 and in the US in June 2019 [1]. This has led to biosimilars of trastuzumab being developed.

Many companies have already developed trastuzumab biosimilars [2]. These include major players such as South Korean biotechnology company Celltrion, which gained European Commission approval for its trastuzumab biosimilar Herzuma (CT P6) in February 2018 [3] and FDA approval in December 2018 [4].

In order to gain regulatory approval for biosimilars a package of data that includes analytical, non-clinical and clinical data is required. To demonstrate biosimilarity for regulatory approval, clinical trials of biosimilars need to be carried out.

As of 30 March 2020, 19 clinical trials relevant to trastuzumab biosimilar development covering 13 different candidate biosimilars and non-originator biologicals are being, or have been, carried out for trastuzumab biosimilars.

An overview of these clinical trials for trastuzumab is given in a GaBI Journal article [5].

References
1. Derbyshire M. Patent expiry dates for biologicals: 2018 update. Generics and Biosimilars Initiative Journal (GaBI Journal). 2019;8(1):24-31. doi:10.5639/gabij.2019.0801.003
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of trastuzumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Aug 28]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-trastuzumab
3. GaBI Online - Generics and Biosimilars Initiative. EC approval for trastuzumab biosimilar Herzuma [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Aug 28]. Available from: www.gabionline.net/Biosimilars/News/EC-approval-for-trastuzumab-biosimilar-Herzuma
4. GaBI Online - Generics and Biosimilars Initiative. FDA approves trastuzumab biosimilar Herzuma [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Aug 28]. Available from: www.gabionline.net/Biosimilars/News/FDA-approves-trastuzumab-biosimilar-Herzuma
5. Derbyshire M. Clinical trials for trastuzumab biosimilars. Generics and Biosimilars Initiative Journal (GaBI Journal). 2020;9(2):84-9. doi:10.5639/gabij.2020.0902.014

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: ClinicalTrials.gov, EU Clinical Trials Register